Previous Page  129 / 490 Next Page
Information
Show Menu
Previous Page 129 / 490 Next Page
Page Background

127

SCIENTIFIC PROGRAMME

| PROGRAMME AND EXHIBITION GUIDE

MONDAY 2 MAY 2016

> Changes of the density CD8+ tumour infiltrating lymphocytes after

neoadjuvant radiochemotherapy

D. Buka (Czech Republic), J. Dvorak, V. Sitorova, I. Richter, I. Sirak

PV-0431

> Mechanisms and abscopal effects of combined mRNA-based radioim-

munotherapy in a syngenic mouse model.

L. Basler (Germany), A. Kowalczyk, M. Fotin-Mleczek, K.J. Kallen,

D. Zips, S.M. Huber

PV-0432

Symposium

MODERN ART BASED ON FUNCTIONAL / BIOLOGICAL IMAGING

10:45 - 11:45 | ROOM 2

This session covers functional imaging for adaptive radiotherapy, with a focus on head and neck cancer.

FDG, hypoxia tracers such as F-MISO and FAZA and tracers for proliferation imaging are interesting

PET tracers that may be used in adaptive radiotherapy and for patient selection in targeted therapy.

How can these imaging modalities be incorporated in an adaptive workflow and what is the rol/

responsibility of the RTT in this process? As example the ARTFORCE trial is described, with a discus-

sion on the use of dose accumulation for assessment of local dose. Future perspectives on imaging and

adaptive replanning will be addressed.

Chair: U. Van der Heide (The Netherlands)

Co-chair: F. Alongi (Italy)

10:45 > Functional imaging for ART; biological bases and potential impact on

clinical outcome

Speaker: B. Hoeben (The Netherlands)

SP-0433

11:05 > Adaptive radiation therapy by the example of head and neck cancer: is

there any role for a RTT?

Speaker: B. Speleers (Belgium)

SP-0434

11:25 > Dosimetric impact of dose painting and replanning: ARTFORCE project

Speaker: J. Sonke (The Netherlands)

SP-0435

Symposium

SECONDARY CANCER AFTER RADIOTHERAPY: FROMCANCER

REGISTRIES TO CLINICAL IMPLICATIONS

10:45 - 11:45 | ROOM 4

Chair: L.P. Muren (Denmark)

Co-chair: A.R. Filippi (Italy)

10:45 > Radiotherapy-related second cancer risks from epidemiological studies,

and their application to newer therapies

Speaker: A. Berrington de González (USA)

SP-0436